Summary
- Trevi Therapeutics has filed its initial S-1 registration statement for an IPO.
- The firm is developing treatment candidates for pruritus and other serious conditions.
- TRVI expects to publish initial trial results for its lead program currently in Phase 2b/3 trials by 1H 2020.
- This idea was discussed in more depth with members of my private investing community, IPO Edge. Start your free trial today »
Quick Take
Trevi Therapeutics (TRVI) intends to raise gross proceeds of $86.25 million from a U.S. IPO, according to an S-1 registration statement.
The firm is developing nalbuphine ER for the treatment of serious neurologically-mediated disease conditions.
TRVI has begun Phase 2b/3 stage trials for its lead program and expects initial data to be published by 1H 2020 at the earliest.
